TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

THIOGUANINE

THIOGUANINE
Oncology Approved 1966-01-18
1
Indication
--
Phase 3 Trials
1
Priority Reviews
60
Years on Market

Details

Status
Prescription
First Approved
1966-01-18
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: THIOGUANINE

THIOGUANINE Approval History

Loading approval history...

What THIOGUANINE Treats

2 indications

THIOGUANINE is approved for 2 conditions since its original approval in 1966. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acute Nonlymphocytic Leukemia
  • Chronic Myelogenous Leukemia
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

THIOGUANINE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

a) Acute Nonlymphocytic Leukemias TABLOID brand Thioguanine is indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. However, it is not recommended for use during maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity (see WARNINGS and ADVERSE REACTIONS). The response to this agent depends upon the age of the patient (younger patients faring better than older) and whether thioguanine is used in previously treated or previously untreated patients. Reliance upon thioguanine alone is seldom justifi...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.